S&P 500   3,780.31 (-0.28%)
DOW   30,269.50 (-0.15%)
QQQ   280.85 (-0.45%)
AAPL   145.76 (-0.23%)
MSFT   248.11 (-0.31%)
META   137.70 (-1.84%)
GOOGL   100.77 (-0.86%)
AMZN   120.35 (-0.61%)
TSLA   238.91 (-4.22%)
NVDA   130.98 (-0.52%)
NIO   15.89 (-5.02%)
BABA   84.06 (-0.06%)
AMD   67.47 (-0.63%)
T   15.90 (-1.18%)
MU   54.61 (+1.20%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.57 (+0.04%)
DIS   100.13 (-1.29%)
AMC   7.41 (-5.36%)
PYPL   93.84 (+1.13%)
PFE   44.00 (-1.03%)
NFLX   233.72 (-2.92%)
S&P 500   3,780.31 (-0.28%)
DOW   30,269.50 (-0.15%)
QQQ   280.85 (-0.45%)
AAPL   145.76 (-0.23%)
MSFT   248.11 (-0.31%)
META   137.70 (-1.84%)
GOOGL   100.77 (-0.86%)
AMZN   120.35 (-0.61%)
TSLA   238.91 (-4.22%)
NVDA   130.98 (-0.52%)
NIO   15.89 (-5.02%)
BABA   84.06 (-0.06%)
AMD   67.47 (-0.63%)
T   15.90 (-1.18%)
MU   54.61 (+1.20%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.57 (+0.04%)
DIS   100.13 (-1.29%)
AMC   7.41 (-5.36%)
PYPL   93.84 (+1.13%)
PFE   44.00 (-1.03%)
NFLX   233.72 (-2.92%)
S&P 500   3,780.31 (-0.28%)
DOW   30,269.50 (-0.15%)
QQQ   280.85 (-0.45%)
AAPL   145.76 (-0.23%)
MSFT   248.11 (-0.31%)
META   137.70 (-1.84%)
GOOGL   100.77 (-0.86%)
AMZN   120.35 (-0.61%)
TSLA   238.91 (-4.22%)
NVDA   130.98 (-0.52%)
NIO   15.89 (-5.02%)
BABA   84.06 (-0.06%)
AMD   67.47 (-0.63%)
T   15.90 (-1.18%)
MU   54.61 (+1.20%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.57 (+0.04%)
DIS   100.13 (-1.29%)
AMC   7.41 (-5.36%)
PYPL   93.84 (+1.13%)
PFE   44.00 (-1.03%)
NFLX   233.72 (-2.92%)
S&P 500   3,780.31 (-0.28%)
DOW   30,269.50 (-0.15%)
QQQ   280.85 (-0.45%)
AAPL   145.76 (-0.23%)
MSFT   248.11 (-0.31%)
META   137.70 (-1.84%)
GOOGL   100.77 (-0.86%)
AMZN   120.35 (-0.61%)
TSLA   238.91 (-4.22%)
NVDA   130.98 (-0.52%)
NIO   15.89 (-5.02%)
BABA   84.06 (-0.06%)
AMD   67.47 (-0.63%)
T   15.90 (-1.18%)
MU   54.61 (+1.20%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.57 (+0.04%)
DIS   100.13 (-1.29%)
AMC   7.41 (-5.36%)
PYPL   93.84 (+1.13%)
PFE   44.00 (-1.03%)
NFLX   233.72 (-2.92%)
NASDAQ:BLRX

BioLineRx - BLRX Stock Forecast, Price & News

$0.92
-0.02 (-2.30%)
(As of 10/5/2022 01:19 PM ET)
Add
Compare
Today's Range
$0.90
$0.95
50-Day Range
$0.88
$1.91
52-Week Range
$0.84
$3.15
Volume
11,104 shs
Average Volume
447,213 shs
Market Capitalization
$43.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

BioLineRx MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
540.3% Upside
$6.00 Price Target
Short Interest
Healthy
0.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.52mentions of BioLineRx in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.53) to ($0.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.29 out of 5 stars

Medical Sector

1048th out of 1,087 stocks

Pharmaceutical Preparations Industry

522nd out of 546 stocks

BLRX stock logo

About BioLineRx (NASDAQ:BLRX) Stock

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Stock News Headlines

BioLineRx (NASDAQ:BLRX) Cut to Sell at StockNews.com
Form 6-K BioLineRx Ltd. For: Sep 21 - StreetInsider.com
BioLineRx Announces $15 Million Registered Direct Offering
BLRX: September NDA - Benzinga
BLRX: September NDA
See More Headlines
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Company Calendar

Last Earnings
12/08/2021
Today
10/05/2022
Next Earnings (Estimated)
11/17/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLRX
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+553.2%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-27,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.43 per share

Miscellaneous

Free Float
47,359,000
Market Cap
$43.99 million
Optionable
Not Optionable
Beta
1.93

Key Executives

  • Mr. Philip A. Serlin CPA (Age 62)
    M.B.A., CPA, MBA, Chief Exec. Officer
    Comp: $644k
  • Ms. Mali Zeevi CPA (Age 46)
    CPA, Chief Financial Officer
    Comp: $391k
  • Dr. Ella Sorani (Age 54)
    Chief Devel. Officer
    Comp: $414k
  • Dr. Abi Vainstein-Haras M.D. (Age 47)
    Chief Medical Officer
    Comp: $391k
  • Advocate Norman Kotler (Age 70)
    Internal Enforcement Officer, Gen. Counsel and Corp. Sec.
  • Ms. Liron Shemesh-Darvish M.B.A.
    Ph.D., Sr. Director & Head of Preclinical Devel.
  • Ms. Jael Birenberg M.Sc.
    Sr. Director & Head of RA, QA and PhV
  • Ms. Tsipi Keren-Lehrer B.Sc.
    L.L.B., Head of BD & Strategic Advisor
  • Ms. Holly W. May M.B.A.
    Chief Commercial Officer
  • Mr. Raziel Fried
    Treasurer & Budgetary Control Director













BLRX Stock - Frequently Asked Questions

What is BioLineRx's stock price forecast for 2022?

0 equities research analysts have issued 12-month price targets for BioLineRx's stock. Their BLRX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 544.9% from the stock's current price.
View analysts price targets for BLRX
or view top-rated stocks among Wall Street analysts.

How have BLRX shares performed in 2022?

BioLineRx's stock was trading at $2.04 on January 1st, 2022. Since then, BLRX stock has decreased by 54.4% and is now trading at $0.9304.
View the best growth stocks for 2022 here
.

When is BioLineRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 17th 2022.
View our BLRX earnings forecast
.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings results on Wednesday, December, 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01.

What other stocks do shareholders of BioLineRx own?
What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $0.93.

How much money does BioLineRx make?

BioLineRx (NASDAQ:BLRX) has a market capitalization of $44.56 million. The biotechnology company earns $-27,050,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The official website for the company is www.biolinerx.com. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101.

This page (NASDAQ:BLRX) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.